{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T02:07:20Z","timestamp":1769911640017,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,31]]},"DOI":"10.7759\/cureus.102706","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T14:00:12Z","timestamp":1769868012000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Filipino Patients With Multiple Sclerosis: A Single-Center Retrospective Case Series"],"prefix":"10.7759","author":[{"given":"Jon Stewart H","family":"Dy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig F","family":"Damian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cymbeline","family":"Perez-Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Multiple sclerosis and other neuroimmunologic disorders","author":"Ropper AH","year":"2023","unstructured":"Ropper AH, Samuels MA, Klein JP, Prasad S. Multiple sclerosis and other neuroimmunologic disorders. Adams and Victor's Principles of Neurology. McGraw-Hill Education, Columbus (OH); 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban X","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J, et al.. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025, 24:850-65. 10.1016\/S1474-4422(25)00270-4","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.824926","article-title":"Therapeutic advances in multiple sclerosis","volume":"13","author":"Yang JH","year":"2022","unstructured":"Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front Neurol. 2022, 13:824926. 10.3389\/fneur.2022.824926","journal-title":"Front Neurol"},{"key":"ref4","unstructured":"Philippine National Formulary Essential Medicines List. (2019). Accessed. June 13, 2025: https:\/\/www.philhealth.gov.ph\/partners\/providers\/pdf\/PNF-EML_11022022.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.87558","article-title":"Autologous hematopoietic stem cell transplantation (aHSCT) in a 56-year-old Filipino female with relapsing-remitting multiple sclerosis: a case report","volume":"17","author":"Dy JS","year":"2025","unstructured":"Dy JS, Cope PM, Perez-Santiago C, Lopez FF. Autologous hematopoietic stem cell transplantation (aHSCT) in a 56-year-old Filipino female with relapsing-remitting multiple sclerosis: a case report. Cureus. 2025, 17:e87558. 10.7759\/cureus.87558","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant A","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al.. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018, 90:777-88. 10.1212\/WNL.0000000000005347","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105703","article-title":"Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates","volume":"88","author":"Jacob A","year":"2024","unstructured":"Jacob A, Shatila AO, Inshasi J, et al.. Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates. Mult Scler Relat Disord. 2024, 88:105703. 10.1016\/j.msard.2024.105703","journal-title":"Mult Scler Relat Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.4025","article-title":"Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society","volume":"78","author":"Miller AE","year":"2021","unstructured":"Miller AE, Chitnis T, Cohen BA, Costello K, Sicotte NL, Stacom R. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society. JAMA Neurol. 2021, 78:241-6. 10.1001\/jamaneurol.2020.4025","journal-title":"JAMA Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt RK","year":"2019","unstructured":"Burt RK, Balabanov R, Burman J, et al.. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019, 321:165-74. 10.1001\/jama.2018.18743","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106542","article-title":"Comparative analysis of five-year clinical outcomes of autologous hematopoietic stem cell transplantation and alemtuzumab in multiple sclerosis patients","volume":"100","author":"Manazo\u011flu HC","year":"2025","unstructured":"Manazo\u011flu HC, \u0130\u015fkan G, G\u00fcnd\u00fcz T, et al.. Comparative analysis of five-year clinical outcomes of autologous hematopoietic stem cell transplantation and alemtuzumab in multiple sclerosis patients. Mult Scler Relat Disord. 2025, 100:106542. 10.1016\/j.msard.2025.106542","journal-title":"Mult Scler Relat Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104932","article-title":"Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis?","volume":"78","author":"Mariottini A","year":"2023","unstructured":"Mariottini A, Muraro PA, Saccardi R. Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis?. Mult Scler Relat Disord. 2023, 78:104932. 10.1016\/j.msard.2023.104932","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1184","article-title":"Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis","volume":"80","author":"Kalincik T","year":"2023","unstructured":"Kalincik T, Sharmin S, Roos I, et al.. Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurol. 2023, 80:702-13. 10.1001\/jamaneurol.2023.1184","journal-title":"JAMA Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27247","article-title":"Effectiveness of autologous hematopoietic stem cell transplantation versus alemtuzumab and ocrelizumab in relapsing multiple sclerosis: a single-center cohort study","volume":"98","author":"Muraro PA","year":"2025","unstructured":"Muraro PA, Zito A, Signori A, et al.. Effectiveness of autologous hematopoietic stem cell transplantation versus alemtuzumab and ocrelizumab in relapsing multiple sclerosis: a single-center cohort study. Ann Neurol. 2025, 98:294-307. 10.1002\/ana.27247","journal-title":"Ann Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.250","article-title":"Evaluation of the effect of autologous hematopoietic stem cell transplant on symptom severity using MSWS-12, AMSQ, and SymptomScreen in multiple sclerosis patients","volume":"31","author":"Cruz-P\u00e9rez GE","year":"2025","unstructured":"Cruz-P\u00e9rez GE, Gallardo-Perez MM, Garc\u00eda-V\u00e9lez D, et al.. Evaluation of the effect of autologous hematopoietic stem cell transplant on symptom severity using MSWS-12, AMSQ, and SymptomScreen in multiple sclerosis patients. Transplant Cell Ther. 2025, 31:163. 10.1016\/j.jtct.2025.01.250","journal-title":"Transplant Cell Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449427-clinical-outcomes-of-autologous-hematopoietic-stem-cell-transplantation-in-filipino-patients-with-multiple-sclerosis-a-single-center-retrospective-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T14:00:13Z","timestamp":1769868013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449427-clinical-outcomes-of-autologous-hematopoietic-stem-cell-transplantation-in-filipino-patients-with-multiple-sclerosis-a-single-center-retrospective-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.102706","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,31]]}}}